Drug Profile
Ambrisentan/tadalafil - GSK
Alternative Names: Tadalafil/ambrisentanLatest Information Update: 02 Jul 2023
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Developer GSK; Hammersmith Medicines Research
- Class Antihypertensives; Benzodioxoles; Carbolines; Indoles; Phenylpropionates; Pyridazines; Small molecules
- Mechanism of Action Endothelin A receptor antagonists; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pulmonary hypertension
Most Recent Events
- 28 Apr 2019 No recent reports of development identified for phase-I development in Pulmonary-hypertension(In volunteers) in United Kingdom (PO, Tablet)
- 04 Aug 2017 GlaxoSmithKline completes a phase I trial in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)
- 01 Mar 2016 Phase-I clinical trials in Pulmonary hypertension (In volunteers) in United Kingdom (PO) (NCT02688387)